Acasă › Leucemie mieloasă acută › California › Baldwin Park
Studii clinice pentru Leucemie mieloasă acută în Baldwin Park, CA
40 studii pentru Leucemie mieloasă acută caută participanți în și în jurul orașului Baldwin Park (în aproximativ 50 km). Deschideți un studiu pentru a vedea criteriile de eligibilitate și cum să contactați echipa de cercetare.
Text oficial al studiului (în engleză)
A Study to Assess Adverse Events and Change in Disease Activity When Intravenous (IV) Pivekimab Sunirine is Given in Combination With Oral Venetoclax and IV or Subcutaneous Azacitidine in Adult Participants With Acute Myeloid Leukemia (AML)
În curs de recrutareFaza 2/3
- City of Hope National Medical Center /ID# 279568, Duarte · La 4 mi distanță
A Phase 1 Study of Orca-Q in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
În curs de recrutareFaza 1
- City of Hope, Duarte · La 4 mi distanță
A Phase 1 Study of AOH1996 in Patients With Relapsed/Refractory Acute Myeloid Leukemia
În curs de recrutareFaza 1
- City of Hope Medical Center, Duarte · La 4 mi distanță
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
În curs de recrutareFaza 3
- Clinical Trial Site, Duarte · La 4 mi distanță
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
În curs de recrutareFaza 3
- City of Hope, Duarte · La 4 mi distanță
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
În curs de recrutareFaza 3
- City of Hope Comprehensive Cancer Center, Duarte · La 4 mi distanță
(Apex) Bezuclastinib in Patients With Advanced Systemic Mastocytosis
În curs de recrutareFaza 2
- City of Hope Comprehensive Cancer Center, Duarte · La 4 mi distanță
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
În curs de recrutareFaza 1
- City of Hope National Medical Center, Duarte · La 4 mi distanță
The Lowest Effective Dose of Post-Transplantation Cyclophosphamide in Combination With Sirolimus and Mycophenolate Mofetil as Graft-Versus-Host Disease Prophylaxis After Reduced Intensity Conditioning and Peripheral Blood Stem Cell Transplantation
În curs de recrutareFaza 1/2Voluntari sănătoși bineveniți
- City of Hope, Duarte · La 4 mi distanță
A Study to Assess the Safety, Tolerability, and Antileukemic Activity of Debio 1562M in Participants With Acute Myeloid Leukemia (AML)
În curs de recrutareFaza 1/2
- City of Hope Comprehensive Cancer Center, Duarte · La 4 mi distanță
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
În curs de recrutareFaza 1/2
- City of Hope National Medical Center, Duarte · La 4 mi distanță
MiRisten for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia
În curs de recrutareFaza 1
- City of Hope Medical Center, Duarte · La 4 mi distanță
Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML
În curs de recrutareFaza 1
- City of Hope, Duarte · La 4 mi distanță
8-Chloroadenosine in Combination With Venetoclax for the Treatment of Patients With Relapsed/Refractory Acute Myeloid Leukemia
În curs de recrutareFaza 1
- City of Hope Medical Center, Duarte · La 4 mi distanță
Individualized AML Treatment
În curs de recrutareStudiu observațional
- City of Hope Medical Center, Duarte · La 4 mi distanță
Total Marrow and Lymphoid Irradiation in Combination With Fludarabine and Melphalan as Conditioning for Allogeneic Peripheral Blood Stem Cell Hematopoietic Cell Transplant in Older Patients With Refractory and Relapsed Acute Myeloid Leukemia and High-risk Myelodysplastic Syndrome
În curs de recrutareFaza 2
- City of Hope Medical Center, Duarte · La 4 mi distanță
225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome
În curs de recrutareFaza 1
- City of Hope Medical Center, Duarte · La 4 mi distanță
A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant
În curs de recrutareFaza 1Voluntari sănătoși bineveniți
- City of Hope Medical Center, Duarte · La 4 mi distanță
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
În curs de recrutareFaza 3
- City of Hope Comprehensive Cancer Center - Duarte, Duarte · La 4 mi distanță
Tagraxofusp and Azacitidine for Maintenance Treatment in Patients With CD123 Positive AML and MDS Following Donor Hematopoietic Cell Transplant
În curs de recrutareFaza 1
- City of Hope Medical Center, Duarte · La 4 mi distanță
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
În curs de recrutareStudiu observațional
- City of Hope, Duarte · La 4 mi distanță
Emapalumab With Post-Transplant Cyclophosphamide, Tacrolimus and Mycophenolate Mofetil for the Prevention of Graft-versus-Host Disease After Donor Reduced-Intensity Hematopoietic Cell Transplant
În curs de recrutareFaza 1
- City of Hope Medical Center, Duarte · La 4 mi distanță
Vedolizumab Plus Post-transplant Cyclophosphamide and Short Course Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation After Reduced Intensity Conditioning
În curs de recrutareFaza 2
- City of Hope Medical Center, Duarte · La 4 mi distanță
A Study of Revumenib and Mezigdomide in People With Leukemia
În curs de recrutareFaza 1/2
- City of Hope Cancer Center (Data collection only), Duarte · La 4 mi distanță
SL-401 in Combination With Azacitidine or Azacitidine/Venetoclax in Acute Myeloid Leukemia (AML), High-Risk Myelodysplastic Syndrome (MDS) or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
În curs de recrutareFaza 1
- City of Hope, Duarte · La 4 mi distanță
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
În curs de recrutareFaza 1Voluntari sănătoși bineveniți
- City of Hope Medical Center, Duarte · La 4 mi distanță
Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
În curs de recrutareFaza 1
- City of Hope, Duarte · La 4 mi distanță
A Study of GLB-001 in Patients With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher Risk Myelodysplastic Syndromes
În curs de recrutareFaza 1
- City of Hope Medical Center, Duarte · La 4 mi distanță
A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
În curs de recrutareFaza 2
- City of Hope, Duarte · La 4 mi distanță
A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
În curs de recrutareFaza 1
- City of Hope, Duarte · La 4 mi distanță
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
În curs de recrutareFaza 2Voluntari sănătoși bineveniți
- City of Hope Medical Center, Duarte · La 4 mi distanță
CD33-CAR T Cell Therapy for the Treatment of Recurrent or Refractory Acute Myeloid Leukemia
În curs de recrutareFaza 1
- City of Hope Medical Center, Duarte · La 4 mi distanță
Olutasidenib for the Treatment of Patients With IDH1 Mutated AML, MDS or CMML After Donor Hematopoietic Cell Transplant
În curs de recrutareFaza 1
- City of Hope Medical Center, Duarte · La 4 mi distanță
Revumenib for the Treatment of Acute Leukemia in Patients Post-Allogeneic Stem Cell Transplant
În curs de recrutareFaza 1
- City of Hope Medical Center, Duarte · La 4 mi distanță
Safety of MT-401-OTS in Patients With Relapsed AML or MDS
În curs de recrutareFaza 1
- City of Hope Center (City of Hope National Medical Center, City of Hope Medical Center), Duarte · La 4 mi distanță
Ruxolitinib With Tacrolimus and Methotrexate for the Prevention of Graft Versus Host Disease in Pediatric and Young Adult Patients Undergoing Allogeneic Hematopoietic Cell Transplant for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Myelodysplastic Syndrome
În curs de recrutareFaza 2
- City of Hope Medical Center, Duarte · La 4 mi distanță
Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia
În curs de recrutareFaza 1
- City of Hope - Duarte, Duarte · La 4 mi distanță
A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome
În curs de recrutareFaza 1
- City of Hope Medical Center, Duarte · La 4 mi distanță
Study of REM-422 in Patients With AML or Higher Risk MDS
În curs de recrutareFaza 1
- City of Hope, Duarte · La 4 mi distanță
A Study of BTX-A51 in People With Relapsed or Refractory Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
În curs de recrutareFaza 1
- City of Hope National Medical Center, Duarte · La 4 mi distanță
Studii pentru Leucemie mieloasă acută în alte orașe
- Houston, TX85 studii
- New York City, NY51 studii
- Boston, MA44 studii
- Seattle, WA41 studii
- Columbus, OH35 studii
- Philadelphia, PA34 studii
- Durham, NC33 studii
- Atlanta, GA31 studii
- Tampa, FL29 studii
- Chicago, IL26 studii
- Portland, OR25 studii
- Washington, DC24 studii
Alte studii în Baldwin Park
- Cancer de sân44 studii
- Cancer colorectal37 studii
- Cancer pulmonar cu celule non-pătrate36 studii
- Cancer (toate tipurile)34 studii
- Cancer de prostată30 studii
- Cancer metastatic30 studii
- Sindroame mielodisplastice26 studii
- Cancer ovarian25 studii
- Cancer pulmonar24 studii
- Mielom multiplu23 studii
- Cancer gastric22 studii
- Leucemie limfoblastică acută21 studii
Sursă: ClinicalTrials.gov, date preluate la 6 oct. 2026. Fiecare studiu are propriile criterii de eligibilitate; echipa de cercetare decide cine poate participa.